Renner M - Search Results

1

Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.

Schüle S, Renner M, Longhurst S, Narayanan G. Schüle S, et al. Among authors: renner m. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):30-7. doi: 10.1007/s00103-009-0988-0. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010. PMID: 20012927

2

Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products.

Anliker B, Childs L, Rau J, Renner M, Schüle S, Schuessler-Lenz M, Sebe A. Anliker B, et al. Among authors: renner m. CRISPR J. 2022 Jun;5(3):364-376. doi: 10.1089/crispr.2021.0148. Epub 2022 Apr 22. CRISPR J. 2022. PMID: 35452274 Review.

3

Safety assessment of biolistic DNA vaccination.

Langer B, Renner M, Scherer J, Schüle S, Cichutek K. Langer B, et al. Among authors: renner m. Methods Mol Biol. 2013;940:371-88. doi: 10.1007/978-1-62703-110-3_27. Methods Mol Biol. 2013. PMID: 23104355 Review.

4

The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.

Aiuti A, Cossu G, de Felipe P, Galli MC, Narayanan G, Renner M, Stahlbom A, Schneider CK, Voltz-Girolt C. Aiuti A, et al. Among authors: renner m. Hum Gene Ther Clin Dev. 2013 Jun;24(2):47-54. doi: 10.1089/humc.2013.119. Hum Gene Ther Clin Dev. 2013. PMID: 23862696 Free article.

5

Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study.

Hlavatý J, Tonar Z, Renner M, Panitz S, Petznek H, Schweizer M, Schüle S, Kloke BP, Moldzio R, Witter K. Hlavatý J, et al. Among authors: renner m. Histochem Cell Biol. 2017 Sep;148(3):313-329. doi: 10.1007/s00418-017-1569-1. Epub 2017 Apr 10. Histochem Cell Biol. 2017. PMID: 28397143 Free PMC article.

6

Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.

Renner M, Anliker B, Sanzenbacher R, Schuele S. Renner M, et al. Adv Exp Med Biol. 2015;871:87-101. doi: 10.1007/978-3-319-18618-4_5. Adv Exp Med Biol. 2015. PMID: 26374214 Review.

7

Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.

Salmikangas P, Schuessler-Lenz M, Ruiz S, Celis P, Reischl I, Menezes-Ferreira M, Flory E, Renner M, Ferry N. Salmikangas P, et al. Among authors: renner m. Adv Exp Med Biol. 2015;871:103-30. doi: 10.1007/978-3-319-18618-4_6. Adv Exp Med Biol. 2015. PMID: 26374215 Review.

8

[Therapeutic approaches using genetically modified cells].

Anliker B, Renner M, Schweizer M. Anliker B, et al. Among authors: renner m. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1274-80. doi: 10.1007/s00103-015-2245-z. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID: 26349563 Review. German.

9

[Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects].

Sebe A, Anliker B, Rau J, Renner M. Sebe A, et al. Among authors: renner m. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1403-1411. doi: 10.1007/s00103-020-03230-8. Epub 2020 Oct 16. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 33067665 Free PMC article. Review. German.

10

Cell therapy clinical trials in Germany--Critical aspects of quality data content: Summary of meeting presentation.

Renner M. Renner M. Biologicals. 2015 Sep;43(5):429-32. doi: 10.1016/j.biologicals.2015.05.001. Epub 2015 Jun 1. Biologicals. 2015. PMID: 26044762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

356 results

Search Page

Filters